{
    "nctId": "NCT00438477",
    "briefTitle": "Injection Methods in Finding the Sentinel Lymph Node During Lymphatic Mapping and Sentinel Lymph Node Biopsy in Patients With Invasive Breast Cancer",
    "officialTitle": "A Preliminary Study To Explore Subareolar Injection As The Site For Lymphatic Mapping And Sentinel Lymph Node Biopsy In Patients With Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "DIAGNOSTIC",
    "enrollmentCount": 74,
    "primaryOutcomeMeasure": "Lymphatic drainage patterns as determined by peritumoral and subareolar injections",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Patients must have either pathologic, radiologic or clinical evidence of breast cancer with invasion, suspicious for invasion or microinvasion.\n2. Patients who are candidates for a total mastectomy or segmental mastectomy or axillary dissection.\n3. Patients who have undergone neoadjuvant chemotherapy who have an FNA confirmed lymph node positive for metastatic disease prior to induction chemotherapy and are then found to have grossly palpable disease but are ultrasound node negative at time of study entry.\n4. Patients must sign an informed consent and be registered before the procedure is performed.\n\nExclusion Criteria:\n\n1. A pregnancy test will be required preoperatively in women of childbearing potential and patients who are pregnant will be excluded from this study.\n2. Patients who have undergone neoadjuvant chemotherapy who have an FNA confirmed lymph node metastatic disease prior to induction chemotherapy and are then found to have grossly suspicious palpable disease and are ultrasound node positive at the time of study entry.\n3. Patients with known allergy to isosulfan blue dye or any related compounds.",
    "sex": "ALL",
    "minimumAge": "N/A",
    "stdAges": "CHILD, ADULT, OLDER_ADULT"
}